AAAAAA

   
Results: 1-15 |
Results: 15
Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals
Authors: Veldkamp, AI van Heeswijk, RPG Mulder, JW Meenhorst, PL Schreij, G van der Geest, S Lange, JMA Beijnen, JH Hoetelmans, RMW
Citation: Ai. Veldkamp et al., Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals, J ACQ IMM D, 27(4), 2001, pp. 344-349
Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1
Authors: van Praag, RME van Heeswijk, RPG Jurriaans, S Lange, JMA Hoetelmans, RMW Prins, JM
Citation: Rme. Van Praag et al., Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1, CLIN INF D, 33(8), 2001, pp. E91-E92
Limited sampling strategies for the estimation of the systemic exposure tothe HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine
Authors: Veldkamp, AI van Heeswijk, RPG Mulder, JW Meenhorst, PL Hoetelmans, RMW Lange, JMA Beijnen, JH
Citation: Ai. Veldkamp et al., Limited sampling strategies for the estimation of the systemic exposure tothe HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine, THER DRUG M, 23(6), 2001, pp. 606-611
Saliva as an alternative body fluid for therapeutic drug monitoring of thenonnucleoside reverse transcription inhibitor nevirapine
Authors: van Heeswijk, RPG Veldkamp, AI Mulder, JW Meenhorst, PL Beijnen, JH Lange, JMA Hoetelmans, RMW
Citation: Rpg. Van Heeswijk et al., Saliva as an alternative body fluid for therapeutic drug monitoring of thenonnucleoside reverse transcription inhibitor nevirapine, THER DRUG M, 23(3), 2001, pp. 255-258
Nevirapine plus didanosine: Once or twice daily combination?
Authors: van Heeswijk, RPG Veldkamp, AI Mulder, JW Meenhorst, PL Wit, FWNM Reiss, P Lange, JMA Kwakkelstein, MO Beijnen, JH Hoetelmans, RMW
Citation: Rpg. Van Heeswijk et al., Nevirapine plus didanosine: Once or twice daily combination?, J ACQ IMM D, 25(1), 2000, pp. 93-95
Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study
Authors: van Heeswijk, RPG Veldkamp, AI Mulder, JW Meenhorst, PL Lange, JMA Beijnen, JH Hoetelmans, RMW
Citation: Rpg. Van Heeswijk et al., Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study, AIDS, 14(9), 2000, pp. F103-F110
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals
Authors: van Heeswijk, RPG Veldkamp, AI Mulder, JW Meenhorst, PL Wit, FWNM Lange, JMA Danner, SA Foudraine, NA Kwakkelstein, MO Reiss, P Beijnen, JH Hoetelmans, RMW
Citation: Rpg. Van Heeswijk et al., The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals, AIDS, 14(8), 2000, pp. F77-F82
Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir
Authors: Gisolf, EH van Heeswijk, RPG Hoetelmans, RWM Danner, SA
Citation: Eh. Gisolf et al., Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir, AIDS, 14(7), 2000, pp. 801-805
Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men
Authors: Taylor, S van Heeswijk, RPG Hoetelmans, RMW Workman, J Drake, SM White, DJ Pillay, D
Citation: S. Taylor et al., Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men, AIDS, 14(13), 2000, pp. 1979-1984
Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir
Authors: Koks, CHW van Heeswijk, RPG Veldkamp, AI Meenhorst, PL Mulder, JW van der Meer, JTM Beijnen, JH Hoetelmans, RMW
Citation: Chw. Koks et al., Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir, AIDS, 14(1), 2000, pp. 89-90
Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection
Authors: Veldkamp, AI van Heeswijk, RPG Meenhorst, PL Mulder, JW Lange, JMA Beijnen, JH Hoetelmans, RMW
Citation: Ai. Veldkamp et al., Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection, J CHROMAT B, 734(1), 1999, pp. 55-61
Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection
Authors: Veldkamp, AI van Heeswijk, RPG Hoetelmans, RMW Meenhorst, PL Mulder, JW Lange, JMA Beijnen, JH
Citation: Ai. Veldkamp et al., Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection, J CHROMAT B, 727(1-2), 1999, pp. 151-157
Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma - drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study
Authors: Panday, VRN Hoetelmans, RMW van Heeswijk, RPG Meenhorst, PL Inghels, M Mulder, JW Beijnen, JH
Citation: Vrn. Panday et al., Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma - drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study, CANC CHEMOT, 43(6), 1999, pp. 516-519
The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals
Authors: van Heeswijk, RPG Veldkamp, AI Hoetelmans, RMW Mulder, JW Schreij, G Hsu, A Lange, JMA Beijnen, JH Meenhorst, PL
Citation: Rpg. Van Heeswijk et al., The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals, AIDS, 13(14), 1999, pp. F95-F99
Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma byion-pair high-performance liquid chromatography with ultraviolet detection
Authors: van Heeswijk, RPG Hoetelmans, RMW Harms, R Meenhorst, PL Mulder, JW Lange, JMA Beijnen, JH
Citation: Rpg. Van Heeswijk et al., Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma byion-pair high-performance liquid chromatography with ultraviolet detection, J CHROMAT B, 719(1-2), 1998, pp. 159-168
Risultati: 1-15 |